62
Participants
Start Date
February 4, 2022
Primary Completion Date
July 31, 2026
Study Completion Date
July 31, 2027
Lurbinectedin
Dosage per protocol, escalation per protocol, IV over 60 minutes (± 5 minute infusion window), schedule per protocol
Doxorubicin
Dosage per protocol, IV per institutional standards of practice and the FDA package insert, schedule per protocol
Memorial Sloan Kettering, New York
Mayo Jacksonville, Jacksonville
Mayo Rochester, Rochester
Mayo Arizona, Phoenix
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Collaborators (1)
Jazz Pharmaceuticals
INDUSTRY
Massachusetts General Hospital
OTHER